| 000 | 01184 a2200325 4500 | ||
|---|---|---|---|
| 005 | 20250517224337.0 | ||
| 264 | 0 | _c20190617 | |
| 008 | 201906s 0 0 eng d | ||
| 022 | _a2164-554X | ||
| 024 | 7 |
_a10.1080/21645515.2018.1493415 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLiu, Shuang | |
| 245 | 0 | 0 |
_aImmunotherapy of Guillain-Barré syndrome. _h[electronic resource] |
| 260 |
_bHuman vaccines & immunotherapeutics _c2018 |
||
| 300 |
_a2568-2579 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 |
_aChemotaxis, Leukocyte _xdrug effects |
| 650 | 0 | 4 |
_aGuillain-Barre Syndrome _xcomplications |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunoglobulins, Intravenous _xtherapeutic use |
| 650 | 0 | 4 |
_aImmunologic Factors _xpharmacology |
| 650 | 0 | 4 |
_aImmunotherapy _xmethods |
| 650 | 0 | 4 | _aPlasma Exchange |
| 650 | 0 | 4 | _aSeverity of Illness Index |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aDong, Chaoling | |
| 700 | 1 | _aUbogu, Eroboghene Ekamereno | |
| 773 | 0 |
_tHuman vaccines & immunotherapeutics _gvol. 14 _gno. 11 _gp. 2568-2579 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1080/21645515.2018.1493415 _zAvailable from publisher's website |
| 999 |
_c28579916 _d28579916 |
||